The STAR Trial

The STAR trial is a clinical study which closely evaluated 126 patients implanted with Inspire therapy. The STAR trial was conducted at 22 leading medical centers in the United States and Europe. STAR trial results have been published in the January 9th, 2014 edition of the New England Journal of Medicine. Over the initial 12 month follow-up period in the study, the majority of patients implanted with Inspire therapy experienced reductions in sleep apnea events and improvements in quality of life measures.

Inspire Therapy is CE Marked and approved for sale in Europe. It has not yet been approved for sale in the United States, but is currently being reviewed by the Food and Drug Administration (FDA). If you would like to stay informed of Inspire’s progress, click one of the buttons below: